Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 27, 2021

Quizartinib With Azacitidine or Low-Dose Cytarabine for the Treatment of AML and MDS



Additional Info

Disclosure statements are available on the authors' profiles:

A Phase I/II Study of the Combination of Quizartinib With Azacitidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Haematologica 2021 Apr 15;[EPub Ahead of Print], M Swaminathan, HM Kantarjian, M Levis, V Guerra, G Borthakur, Y Alvarado, CD DiNardo, T Kadia, G Garcia-Manero, M Ohanian, N Daver, M Konopleva, N Pemmaraju, A Ferrajoli, M Andreeff, N Jain, Z Estrov, EJ Jabbour, WG Wierda, S Pierce, MR Pinsoy, L Xiao, F Ravandi, JE Cortes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading